Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)

Published on Sep 1, 2018in Pharmacological Research5.574
· DOI :10.1016/j.phrs.2018.07.016
Paolo Gelosa23
Estimated H-index: 23
Laura Castiglioni10
Estimated H-index: 10
(University of Milan)
+ 4 AuthorsStefano Bellosta26
Estimated H-index: 26
(University of Milan)
Abstract The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and significant variability in dose-response among individuals, in addition to a potential for drug-drug interactions). Therefore, the need for non-vitamin K antagonist oral anticoagulants (NOACs) with a rapid onset of antithrombotic effects and a predictable pharmacokinetic (PK) and pharmacodynamic (PD) profile led to the approval of five new drugs: the direct factor Xa (F-Xa) inhibitors rivaroxaban, apixaban, edoxaban and betrixaban (newly approved by FDA) and the direct thrombin (factor-IIa) inhibitor dabigatran etexilate. The advantages of NOACs over warfarin are a fixed-dosage, the absence of the need for drug monitoring for changes in anti-coagulation and fewer clinically significant PK and PD drug–drug interactions. NOACs exposure will likely be increased by the administration of strong P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4-inhibitors and may increase the risk of bleeds. On the contrary, P-gp inducers could significantly decrease the NOACs plasma concentration with an associated reduction in their anticoagulant effects. This manuscript gives an overview of NOACs PK profiles and their drug-drug interactions potential. This is meant to be of help to physicians in choosing the best therapeutic approach for their patients.
  • References (165)
  • Citations (8)
📖 Papers frequently viewed together
14 Citations
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Serge Korjian (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 12
#2Eugene Braunwald (Brigham and Women's Hospital)H-Index: 212
Last. C. Michael Gibson (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 93
view all 8 authors...
Background:Despite dual antiplatelet therapy, persistent thrombin generation and thrombin-mediated platelet activation account in part for the residual risk of atherothrombotic disease among patients with prior acute coronary syndrome (ACS). Inhibition of thrombin generation among high-risk ACS patients (biomarker-positive ACS) with the factor Xa inhibitor rivaroxaban may limit ongoing thrombus formation and myocardial necrosis and thereby improve clinical outcomes.Objectives and methods:ATLAS A...
3 CitationsSource
#1Jan SteffelH-Index: 29
#2Peter Verhamme (Katholieke Universiteit Leuven)H-Index: 32
Last. Hein Heidbuchel (University of Hasselt)H-Index: 66
view all 15 authors...
[Steffel, Jan] Univ Heart Ctr Zurich, Dept Cardiol, Ramistr 100, CH-8091 Zurych, Switzerland. [Verhamme, Peter; Sinnaeve, Peter] Univ Leuven, Dept Cardiovasc Sci, Leuven, Belgium. [Potpara, Tatjana S.] Univ Belgrade, Sch Med, Belgrad, Serbia. [Albaladejo, Pierre] Grenoble Alps Univ Hosp, Grenoble, France. [Antz, Matthias] City Hosp Braunschweig, Braunschweig, Germany. [Desteghe, Lien; Heidbuchel, Hein] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Haeusler, Karl Georg] Charite, Ctr Stroke...
44 CitationsSource
#1Farhan Shahid (University of Birmingham)H-Index: 4
#2Daniele Pastori (University of Birmingham)H-Index: 20
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 141
view all 4 authors...
Abstract Atrial fibrillation (AF) is associated with a 5-fold increase in the risk of ischemic stroke, and AF-related stroke patients have a higher mortality and greater morbidity than patients with non-AF related stroke. AF and vascular disease share a close relationship, with the concomitant presence of both disease states leading to a dramatic rise in future cardiovascular events. Indeed, the presence of peripheral artery disease independently predicts stroke in patients with AF. Myocardial i...
3 CitationsSource
#1Marin Nishimura (UCSD: University of California, San Diego)H-Index: 4
#2Jonathan C. Hsu (UCSD: University of California, San Diego)H-Index: 17
Over the past decade, there have been tremendous advancements in anticoagulation therapies for stroke prevention in patients with atrial fibrillation (AF). Although the non–vitamin K antagonist oral anticoagulants (NOACs) demonstrated favorable clinical outcomes compared with warfarin overall, the decision to anticoagulate and the choice of appropriate agent in patients with AF and concomitant chronic kidney disease (CKD) or end-stage renal disease (ESRD) are a particularly complex issue. CKD an...
9 CitationsSource
#1Shang-Hung Chang (CGU: Chang Gung University)H-Index: 14
#2I-Jun Chou (CGU: Chang Gung University)H-Index: 16
Last. Chang-Fu KuoH-Index: 27
view all 8 authors...
Importance Non–vitamin K oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk. Objective To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation. Design, Setting, and Participants Retrospective cohort study using data from the Taiwan National Health Insurance database and including 91 330 patients with...
67 CitationsSource
#1Takako Shimizu (Daiichi Sankyo)H-Index: 1
#2Masaya Tachibana (Daiichi Sankyo)H-Index: 4
Last. Kazutaka Yoshihara (Daiichi Sankyo)H-Index: 6
view all 5 authors...
This is a population pharmacokinetic (PopPK) analysis to predict PK of edoxaban, a direct-acting oral anticoagulant, in nonvalvular atrial fibrillation (NVAF) patients with severe renal impairment (SRI; creatinine clearance [CLcr] <30 mL/min). Data from a phase 3 study recently conducted in Japanese NVAF patients (n = 90), including patients with SRI, were used to update the ENGAGE PopPK model that had been developed based on pooled data from the phase 3 ENGAGE AF-TIMI 48 study and 13 phase 1 PK...
7 CitationsSource
#1Songie ChoiH-Index: 2
#2Dal-Seok OhH-Index: 14
Last. Ui Min JerngH-Index: 1
view all 3 authors...
Objectives The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin. Methods Three electronic databases were searched to identify relevant trials. Two reviewers independently performed the study selection and data extraction. The risk of bias and reporting quality were also assessed independently by two reviewers using the Cochrane risk of...
9 CitationsSource
#1P. S. S. Rao (University of Findlay)H-Index: 13
#2T. Burkart (University of Findlay)H-Index: 1
Abstract Approximately 900,000 people are affected by some sort of venous thromboembolic (VTE) event every year in the United States. VTE diagnosis used to mean treatment with medications that required routine lab monitoring for safety and efficacy. Activated factor X (FXa) inhibition has emerged as a convenient pathway for management of VTE and currently three FXa inhibitors are available for anticoagulation management - rivaroxaban, apixaban, and edoxaban. Continued development of medications ...
11 CitationsSource
#1Alessandro Di MinnoH-Index: 16
#2Beatrice FrigerioH-Index: 9
Last. Damiano Baldassarre (University of Milan)H-Index: 35
view all 10 authors...
Abstract The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists (VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important because deviations from their narrow therapeutic window can result in bleedings due to over-anticoagulation or thrombosis because of under-anticoagulation. In addition to pharmacodynamic interactions (e.g., augmented bleeding risk for concomitant use of NSAIDs), interactions with drugs, foods, herbs, and over-the-c...
50 CitationsSource
#1Emanuel Raschi (UNIBO: University of Bologna)H-Index: 22
#2Matteo Bianchin (UNIBO: University of Bologna)H-Index: 4
Last. Walter Ageno (University of Insubria)H-Index: 45
view all 5 authors...
Abstract Direct-acting oral anticoagulants (DOACs) were claimed to cause a potential paradigm shift in the therapeutic scenario of patients requiring short- and long-term anticoagulation, by virtue of their pharmacological properties, perceived as innovative. The evidence gathered so far (from pre-approval pivotal trials to real-world post-marketing observational data) consistently confirmed that DOACs are overall comparable to vitamin-K antagonists (VKAs) in terms of safety, efficacy and effect...
6 CitationsSource
Cited By8
#1Yang Hua (Nanjing Medical University)
#2Jin-Yu Sun (Nanjing Medical University)
Last. Xiang-Qing Kong (Nanjing Medical University)
view all 7 authors...
AIMS This meta-analysis was conducted to compare the efficacy and safety of rivaroxaban with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus. METHODS PubMed, Embase, Cochrane Library, and Web of Science databases were systematically searched from the establishment of databases up to 15 October 2019. Studies on efficacy and safety outcomes of rivaroxaban and warfarin were included. Efficacy and safety outcomes, including stroke, ischemic stroke, stroke or systemic embolis...
#1Alberto Corsini (University of Milan)H-Index: 42
#2Nicola Ferri (UNIPD: University of Padua)H-Index: 27
Last. Giuseppe Boriani (University of Modena and Reggio Emilia)H-Index: 59
view all 4 authors...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now spreading in current clinical practice, being indicated for both thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, the contemporary administration of several drugs can cause relevant drug-d...
#1Giuseppe CamporeseH-Index: 17
#2Daniela BernardiH-Index: 13
Last. Fabrizio FabrisH-Index: 31
view all 12 authors...
Abstract No data are available on rivaroxaban use in renal transplant recipients and on its surmised interaction with immunosuppressants. The aim was to investigate potential interactions between rivaroxaban and immunosuppressants in this setting. Renal transplant recipients with a stable renal function treated with rivaroxaban and tacrolimus with or without everolimus were investigated. All drugs and creatinine concentrations were determined daily for 2 weeks after the start of anticoagulation....
#1Ahmad El Alayli (DMC: Detroit Medical Center)
#2Logeswari Neelakandan (DMC: Detroit Medical Center)
Last. Hicham Krayem (DMC: Detroit Medical Center)H-Index: 1
view all 3 authors...
Background. With the rise in the use of direct oral anticoagulants (DOACs), more hemorrhagic complications are being encountered. Since the first description of a case of spontaneous spinal epidural hematoma (SSEH) related to the utilization of DOACs in 2012, there have been few reports describing a similar association. However, no cases so far have reported an association between SSEHs and apixaban. Case Description: A 76-year-old lady, with a history of nonvalvular atrial fibrillation, present...
#1Claire Auditeau (Necker-Enfants Malades Hospital)
#2A. Talbot (University of Paris)
Last. Nicolas Gendron (University of Paris)
view all 5 authors...
Resume Les anticoagulants oraux directs, anti-IIa ou anti-Xa, sont largement utilises dans le traitement et la prevention de la maladie thromboembolique veineuse ainsi que dans la fibrillation atriale non valvulaire. Ils sont caracterises par une action rapide, previsible et un intervalle therapeutique large. Neanmoins, des interactions medicamenteuses theoriques existent puisque les anticoagulants oraux directs sont des substrats de la proteine de transport P-glycoproteine et/ou de certains iso...
#1Kathrin JobskiH-Index: 8
#2Falk HoffmannH-Index: 26
Last. Michael DörksH-Index: 5
view all 4 authors...
Background Vitamin K antagonists (VKAs) are susceptible to drug–drug interactions. Non-VKA oral anticoagulants (NOACs) have a decreased sensitivity to pharmacokinetic interactions and might be therefore considered superior in patients treated with multiple drugs. The objective of this study was to compare the risk of serious bleeding associated with interacting drugs in German nursing home residents treated with VKA or NOAC.
1 CitationsSource
#1Vimal K. Derebail (UNC: University of North Carolina at Chapel Hill)H-Index: 18
#2Michelle N. Rheault (UMN: University of Minnesota)H-Index: 16
Last. Bryce A. Kerlin (OSU: Ohio State University)H-Index: 17
view all 3 authors...
Abstract The anticoagulation field is experiencing a renaissance that began with regulatory approval of the direct thrombin inhibitor, dabigatran, a Direct Oral Anticoagulant (DOAC) in 2010. The DOAC medication class has rapidly evolved to include the additional approval of four direct factor Xa inhibitors. Commensurately, DOAC utilization has grown and collectively account for the majority of new anticoagulant prescriptions. Despite exclusion of moderate-to-severe kidney disease patients from m...
4 CitationsSource
Abstract Use of non-vitamin K antagonist oral anticoagulants (NOACs), including dabigatran etexilate, rivaroxaban, apixaban, edoxaban or betrixaban provides a safe and convenient alternative to the traditional anticoagulation with vitamin K antagonists or heparin derivatives. Many patients receiving long-term seizure prophylaxis with antiepileptic drugs (AEDs) may require anticoagulation with NOACs. Providers caring for these patients need to be informed about potential interactions between AEDs...
#1Alexander J. Sweidan (UCI: University of California, Irvine)H-Index: 2
#2Navneet Singh (UCI: University of California, Irvine)H-Index: 1
Last. Wengui Yu (UCI: University of California, Irvine)H-Index: 10
view all 7 authors...
As intracerebral hemorrahge becomes more frequent as a result of an aging population with greater comorbidities, rapid identification and reversal of precipitators becomes increasingly paramount. The aformentioned population will ever more likely be on some form of anticoagulant therapy. Understanding the mechanisms of these agents and means by which to reverse them early on is critical in managing the acute intracerebral hemorrhage.
#1Kevin Kris Warnakula Olesen (Aarhus University Hospital)H-Index: 5
#2Matt Wheeler (Population Health Research Institute)
Last. John W. Eikelboom (Population Health Research Institute)H-Index: 93
view all 3 authors...